We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Merck KGa A officials say that, ultimately, the SMARTfacturing transformation benefits its customers, patients, and the ...

Merck KGaA's stock remains a 'hold' due to its high valuation, trading at an earnings multiple of around 20 and a 4.5% free ...

Merck KGaA’s top-selling product in 2024 was Erbitux (cetuximab), which generated €1.16bn ($1.25bn) in revenue. The drug – a ...

Merck KGaA is doubling down on AI through a new ... multi-year contract with Genpact for use of its Pharmacovigilance AI products.

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor chemicals and for lab equipment in biotech drug production.

Germany’s Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced research and development expenses in its healthcare segment and ...

As you see on the slide, Merck is on a path to achieving its sustainability ambitions. The amount of people treated with our healthcare products continued to grow, and we just recently announced ...

The board of Merck KGaA (ETR:MRK) has announced that it will pay a dividend of €2.20 per share on the 30th of April. This means the annual payment will be 1.6% of the current stock price ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.